What Is Viking Therapeutics Worth?

What Is Viking Therapeutics Worth?

Creating a valuation estimate for a biotechnology company in Phase 2 trials is as risky as the biotech itself. In the case of Viking Therapeutics (VKTX), I believe the exercise is worth the effort given the rapid adoption of GLP-1 agonists (sometimes referred to as incretins), for the treatment of diabetes and weight loss – … Read more

Why Acasti Pharma Deserves A Deeper Look

Why Acasti Pharma Deserves A Deeper Look

Acasti Pharma (ACST) is a late-stage specialty biotech developing novel therapies for rare diseases, specifically for those who are underserved or lack treatment options. GTX-104 ACST’s lead program, GTX-104, is a room-temperature stable, IV formulation of nimodipine that targets aneurysmal subarachnoid hemorrhage (aSAH), a life-threatening condition where bleeding occurs over the surface of the brain … Read more

Telehealth at the Forefront: The Rise of Weight-Loss Drugs

Telehealth at the Forefront: The Rise of Weight-Loss Drugs

In the transformative landscape of healthcare, the rise of weight-loss medications such as Ozempic and Wegovy has sparked a cultural and business revolution, challenging our perceptions of obesity and medical treatment. These drugs, originally designed for type 2 diabetes management, have unexpectedly become a beacon for those seeking weight loss solutions, leading to a societal … Read more

Multi-Agonist GLP-1s And Metabolic Psychiatry

Multi-Agonist GLP-1s And Metabolic Psychiatry

In recent groundbreaking research, scientists have discovered that the drug Dulaglutide, commonly used to type 2 diabetes mellitus (T2DM), has shown promising results in reversing depression-like behavior and restoring metabolic balance in the hippocampus of mice subjected to chronic mild stress. This study highlights the intricate link between metabolic disorders and mental health, suggesting a … Read more

Insider Insights: Evaluating the Investment Risks of Beam Therapeutics vs. Intensity Therapeutics

Insider Insights: Evaluating the Investment Risks of Beam Therapeutics vs. Intensity Therapeutics

In biotech investing, distilling exceptional opportunities from the average (or worse) ventures requires a keen eye on insider activities, financial health, and clinical progress. Beam Therapeutics (BEAM) presents a case that demands caution, with insider stock sales, a substantial accumulated deficit, and limited clinical advancements raising significant concerns. In contrast, Intensity Therapeutics (INTS) is an … Read more

An Interview With NeuroBo’s CEO To Discuss The Company’s GLP-1 Dual Agonist

An Interview With NeuroBo’s CEO To Discuss The Company’s GLP-1 Dual Agonist

NeuroBo Pharmaceuticals is a clinical stage drug development company with a focus on weight loss and a GLP-1 Dual Agonist. Its most advanced drug candidate, A-1726, is a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of obesity. The IND approval is expected soon with Phase 1 trials commencing shortly thereafter. … Read more